Monoclonal Antibody ALT-100 Shows Early Promise for ARDS in Proof-of-Concept Trial
Key Insights
A proof-of-concept study found the monoclonal antibody ALT-100 significantly increased ventilator-free days in ARDS patients, averaging 21 days versus 14 for placebo.
The 15-patient randomized trial demonstrated ALT-100 reduced inflammatory markers and lowered organ failure scores with a safety profile comparable to placebo.
ALT-100 targets extracellular NAMPT (search), a master regulator of inflammation, putting brakes on excessive immune response without dampening infection-fighting ability.
A monoclonal antibody targeting a master regulator of inflammation has demonstrated encouraging results in a proof-of-concept clinical trial for acute respiratory distress syndrome (search) (ARDS), a life-threatening lung condition that has no FDA-approved pharmacotherapy and carries a nearly 40% mortality rate.
The investigational antibody, called ALT-100, was developed by Joe G.N. Garcia, M.D., associate vice president for research at UF Health and director of The Center for Inflammation Science and Systems Medicine at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology. Results from the early-phase randomized trial were published in the American Journal of Respiratory and Critical Care Medicine.
Trial Design and Key Findings
The study enrolled 15 patients diagnosed with ARDS across academic medical centers in six U.S. cities, including UF Health Shands Hospital (search) in Gainesville. Participants were randomly assigned to receive either a saline placebo or ALT-100.
Over the 28-day observation period, patients in the ALT-100 group experienced significantly greater ventilator-free days — 21 days on average compared to 14 days in the placebo arm. The treatment group also demonstrated reduced inflammatory markers and lower organ failure scores.
"Even though we were only able to enroll 15 patients, the data we are getting is simply incredible," Garcia said. "Particularly the ARDS data showing that the monoclonal antibody improved both ventilator-free days and organ failure scores, because organ failure is the main cause of ARDS-related mortality."
Critically, the safety profile of ALT-100 appeared comparable to that of placebo recipients, an essential finding for a therapy targeting the delicate inflammatory pathways in critically ill patients.
Mechanism of Action: Targeting NAMPT (search)
ALT-100 is a monoclonal antibody that directly targets extracellular NAMPT (search) (nicotinamide phosphoribosyltransferase), a protein Garcia's laboratory identified as a master regulator of the inflammatory response. The discovery traces back to Garcia's tenure as chief of pulmonary and critical care medicine at Johns Hopkins University in the late 1990s, where frustration with the lack of ARDS treatments drove him to investigate gene activity in affected patients.
His research revealed that in patients with mutations impairing NAMPT (search) breakdown, unremitting inflammation — commonly referred to as a "cytokine storm" — could develop, leading to organ failure and death. Unlike some anti-inflammatory medications, ALT-100 does not dampen the body's ability to fight infection; rather, it puts the brakes on an excessive immune response.
"This is a Humira-like drug, targeting the innate immune response, which is why it has profound implications for diseases like cancer, organ fibrosis and so on," Garcia noted. His research groups have since studied the antibody's therapeutic potential in preclinical models of approximately 20 conditions, including liver fibrosis, pregnancy loss, advanced prostate cancer, heart disease, neonatal necrotizing enterocolitis, and lupus-related vasculitis.
Unmet Need and Study Limitations
ARDS occurs when an inflammatory cascade triggered by infection or injury leaks fluid into the lungs, crashing blood oxygen levels. An estimated 500,000 people are diagnosed with ARDS annually in the United States, with 2 million cases globally. The condition was a frequent cause of death during the COVID-19 pandemic.
"There are no FDA-approved therapies to give these patients, and given the unacceptable mortality and pervasiveness of the disease, ARDS treatment remains one of the greatest unmet needs in medicine," Garcia said.
The study carries an important limitation: the small sample size. The research team had aimed to enroll 60 patients, but strict inclusion criteria requiring treatment within six hours of diagnosis caused enrollment delays, and additional funding would have been necessary to recruit more participants.
Next Steps
Beyond the ARDS indication, Garcia has received clearance from the U.S. Food and Drug Administration to study ALT-100 in patients with progressive pulmonary fibrosis, a buildup of scar tissue in the lungs often seen in autoimmune disease and common among ARDS survivors. He now seeks funding for a larger clinical trial to further validate the antibody's efficacy in ARDS.